Aquestive Therapeutics
AQST
60 hedge funds and large institutions have $96.5M invested in Aquestive Therapeutics in 2020 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 11 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 16
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
7% more capital invested
Capital invested by funds: $90M → $96.5M (+$6.57M)
5% more funds holding
Funds holding: 57 → 60 (+3)
4.02% more ownership
Funds ownership: 55.13% → 59.15% (+4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
79% less call options, than puts
Call options by funds: $270K | Put options by funds: $1.32M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$4.1M |
| 2 |
Morgan Stanley
New York
|
+$3.83M |
| 3 |
Charles Schwab
San Francisco,
California
|
+$831K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$828K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$792K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$1.38M |
| 2 |
BlackRock
New York
|
-$1.02M |
| 3 |
Squarepoint
New York
|
-$942K |
| 4 |
Millennium Management
New York
|
-$749K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$220K |
AQST Hedge Fund Activity: Q3 2020 in Review
60 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q3 2020, worth a combined $96.5M — up 7.3% from $90M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new AQST positions and 11 closed out — a net gain of 4 holders — while 22 added to existing stakes and 16 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $4.1M. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $1.38M sold.
- 60 institutional investors held Aquestive Therapeutics (AQST) as of Q3 2020, up from 57 in Q2 2020.
- Funds reported $96.5M of Aquestive Therapeutics stock for Q3 2020, up 7.3% quarter-over-quarter.
- 15 funds opened new Aquestive Therapeutics positions in Q3 2020 and 11 closed out, a net change of +4 holders.
- The largest Aquestive Therapeutics buyer in Q3 2020 was Invesco, an estimated $4.1M added.
- The largest Aquestive Therapeutics seller in Q3 2020 was D.E. Shaw & Co, an estimated $1.38M sold.
Based on aggregated 13F filings for Q3 2020.